Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

We recently published a list of 10 Stocks Grow Firmer Despite Mixed Market Sentiment. In this article, we are going to take a ...

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...

KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...

Market OverviewThe Global Monoclonal Antibodies Market has experienced significant growth over the past few decades, driven ...

How intelligent technologies are transforming the biopharma industry’Life-changing interventions that have previously been ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.